

Hemophilia Articles

** These CDC scientific articles are listed in order of date published, from 1997 to 2004.*

Soucie JM, Cianfrini C, Janco RL et al. Joint range of motion among young males with hemophilia: prevalence and risk factors. *Blood* 2004;103:2467-2473.

Soucie JM, Siwak EB, Hooper WC, Evatt BL, Hollinger FB. Human Parvovirus B19 in young males with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. *Transfusion* 2004;8:1179-1184.

Soucie JM, Cianfrini C, Janco RL, Kulkarni R, Hambleton J, Evatt B, Forsyth A, Geraghty S, Hoots K, Abshire T, Curtis R, Forsberg A, Huszti H, Wagner M, and White GC. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. *Blood*, Apr 2004; 103: 2467 - 2473.

Giangrande P, O'Mahony B, Page D, Evatt B. WFH policy on selection of coagulation factor concentrates: a rebuttal. *Journal of Thrombosis and Haemostasis* 2004; 2: 1023.

Kulkarni R, Soucie JM, Evatt BL. Renal disease among males with hemophilia. *Hemophilia* 2003;9:703-710.

Centers for Disease Control and Prevention. Blood safety monitoring among people with bleeding disorders. *MMWR Morbidity and Mortality Weekly Report* 2002;51:1152-1154.

Evatt BL. Observation from Global Survey 2001: an emerging database for progress. *Haemophilia* 2002;8(2):153-156.

Evatt BL, Hooper WC. Hemostatic aspects of patients with human immunodeficiency virus/acquired immunodeficiency syndrome. In: Kitchens C, Alving B, Kessler C, editors. *Consultative hemostasis and thrombosis*. Philadelphia: WB Saunders; 2002. p. 515-521.

Evatt EL, Furrugia A, Shapiro AD, Wilde JT. *Haemophilia* 2002: emerging risks of treatment. *Haemophilia* 2002;2002(8):221-229.

Chorba TL, Holman RC, Clarke MJ, Evatt BL. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. *American Journal of Hematology* 2001;66(4):229-240.

Heneine W, Switzer WM, Soucie JM, Evatt BL, Shanmugam V, Vazquez Rosales G, Mathews A, Sandstrom P, Folks TM. Evidence of porcine endogenous retroviruses in porcine factor VIII and evaluation of transmission to recipients with hemophilia. *Journal of Infectious Disease* 2001;183:648-652.

Hilgartner MW, Maeder MA, Mahoney EM, Donfield SM, Evatt BL, Hoots WK. Response to measles, mumps, and rubella revaccination among HIV-positive and HIV-negative children and adolescents with hemophilia. Hemophilia Growth and Development study. *American Journal of Hematology* 2001;66(2):92-98.

Nuss R, Soucie JM, Evatt B. Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage. *American Journal of Hematology* 2001;68(37):42.

Soucie JM, Richardson LC, Evatt BL, Linden JV, Ewenstein BM, Stein SF, Leissinger C, Manco-Johnson M, Sexauer CL. Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males. *Transfusion* 2001;41:338-343.

Soucie JM, Symons J, Evatt B, Brettler D, Huszti H, Linden J. Home-based factor infusion therapy and hospitalization for bleeding complications among males with hemophilia. *Haemophilia* 2001;7(2):198-206.

Evatt BL, Robillard L. Establishing hemophilia care in developing countries: using data to overcome the barrier of pessimism. *Hemophilia* 2000;183:1271-1277.

Richardson LC, Evatt BL. Risk of Hepatitis A virus infection in persons with hemophilia receiving plasma-derived products. *Transfusion Medicine Review* 2000;14:64-73.

Soucie JM, Erdman DD, Evatt BL, Anderson LJ, Torok TJ, El-Jamil M, Barnhart E, Tepper M, Burrill HN, Pickett AM, Mengeling WL. Investigation of porcine parvovirus among person with hemophilia receiving Hyate:C porcine factor VIII concentrates. *Transfusion* 2000;40:708-711.

Soucie JM, Nuss R, Evatt B, Abdelhak A, Cowan L, Hill H, Kolakoski M, Wilber N. Mortality among males with hemophilia: relations with source of medical care. *Blood* 2000;96:437-442.

Soucie JM, Rickles FR, Evatt BL. Surveillance for hemophilia and inherited hematologic disorders. In: Thomson EJ, Koury MJ, Burke W, editors. *Genetics and public health in the 21st century*. Oxford University: Oxford University Press; 2000. p. 141-150.

Evatt BL, Austin H, Leon G, Ruiz-Saez A, de Bosch N. Hemophilia treatment. Predicting the long-term risk of HIV exposure by cryoprecipitate. *Hemophilia* 2000;6 Suppl 1:128-32.

Nelson MD, Wilson DA, Kisker CT, Fenstermacher MJ, Lynn HS, Evatt BL, Donfield SM, Maeder MA. Incidence of focal white matter lesions in a population of hemophiliac children and their normal siblings. *Pediatric Radiology* 2000;30:705-709.

Evatt BL, Austin H, Leon G, Ruiz-Saez A, De Bosch N. Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate. *Haemophilia* 1999;5:295-300.

Evatt B, Austin H, Barnhart E, Schonberger L, Sharer L, Jones R, DeArmond S. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. *Transfusion* 1998;38:817-820.

Evatt BL. Prions and hemophilia: assesment of risk. *Haemophilia* 1998;4:628-633.

Evatt BL. Public health and international health-care development for person with hemophilia: operation improvement and operation access. *Haemophilia* 1998;4:suppl 2-suppl 2.

Robertson B, Alter MA, Bell BP, Evatt B, McCaustland KA, Shipiro CN, Sinha SD, Soucie M. Hepatitis A virus sequence detected in clotting factor concentrates associates with disease transmission. *Biologicals* 1998;26:95-99.

Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. *American Journal of Hematology* 1998;59:288-294.

Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt B. Hepatitis A virus infections associated with clotting factor concentrate in the United States. *Transfusion* 1998;38:573-579.

Evatt BL, Hooper WC. Infectious complications of blood products. In: Aledort LM, Madhok R, editors. *Hemophilia*. London: Chapman & Hall Medical; 1997. p. 249-257.